Jazz Pharmaceuticals (JAZZ) Other Non-Current Liabilities (2012 - 2026)

Jazz Pharmaceuticals' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $161.5 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 77.24% year-over-year to $161.5 million; the TTM figure through Mar 2026 stood at $161.5 million (up 77.24% YoY), while the FY2025 annual figure was $124.4 million, up 43.63% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $161.5 million, up from $124.4 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $161.5 million in Q1 2026, with the low at $86.6 million in Q4 2024.
• The 5-year median for Other Non-Current Liabilities is $122.7 million (2023), against an average of $116.6 million.
• The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities decreased 29.41% in 2024, then surged 77.24% in 2026.
• Jazz Pharmaceuticals' Other Non-Current Liabilities stood at $144.0 million in 2022, then dropped by 14.78% to $122.7 million in 2023, then retreated by 29.41% to $86.6 million in 2024, then surged by 43.63% to $124.4 million in 2025, then grew by 29.82% to $161.5 million in 2026.
• Business Quant data shows JAZZ's Other Non-Current Liabilities at $161.5 million in Q1 2026, $124.4 million in Q4 2025, and $108.9 million in Q3 2025.